<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Stock Blog Hub &#187; Mylan</title>
	<atom:link href="http://www.stockbloghub.com/tag/mylan/feed" rel="self" type="application/rss+xml" />
	<link>http://www.stockbloghub.com</link>
	<description>Start Your Investing Research Here!</description>
	<lastBuildDate>Wed, 23 May 2012 20:22:08 +0000</lastBuildDate>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.3.2</generator>
		<item>
		<title>(AMGN) Stock Market News for Dec 15, 2010 &#8211; Market News</title>
		<link>http://www.stockbloghub.com/2010/12/15/amgn-stock-market-news-for-dec-15-2010-market-news/62397</link>
		<comments>http://www.stockbloghub.com/2010/12/15/amgn-stock-market-news-for-dec-15-2010-market-news/62397#comments</comments>
		<pubDate>Wed, 15 Dec 2010 21:04:25 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Abercrombie & Fitch Company]]></category>
		<category><![CDATA[Amgen Inc]]></category>
		<category><![CDATA[AMGN]]></category>
		<category><![CDATA[ANF]]></category>
		<category><![CDATA[BAC]]></category>
		<category><![CDATA[Bank of America Corporation]]></category>
		<category><![CDATA[BBY]]></category>
		<category><![CDATA[BCR]]></category>
		<category><![CDATA[Best Buy Company Inc]]></category>
		<category><![CDATA[C]]></category>
		<category><![CDATA[Citigroup Inc.]]></category>
		<category><![CDATA[Cr Bard Inc]]></category>
		<category><![CDATA[JPM]]></category>
		<category><![CDATA[JPMorgan Chase & Company]]></category>
		<category><![CDATA[M]]></category>
		<category><![CDATA[Macy's]]></category>
		<category><![CDATA[MYL]]></category>
		<category><![CDATA[Mylan]]></category>
		<category><![CDATA[Target Corporation]]></category>
		<category><![CDATA[TGT]]></category>
		<category><![CDATA[Wells Fargo & Company]]></category>
		<category><![CDATA[WFC]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=62397</guid>
		<description><![CDATA[On Tuesday, the markets closed almost flat after a muted view from the Federal Reserve about the economic recovery. However, stocks were helped marginally by the positive report on retail spending. The Dow Jones Industrial Average rose 0.4% to 11,476.54.The Standard &#38; Poor&#8217;s 500 was up 0.1% to 1,241.59.The Nasdaq Composite gained 0.1% to 2,627.72. On the New York Stock Exchange, breadth of the market was negatively biased as for every 17 stocks that fell, 13 stocks ended in the green with a consolidated volume of 957 million shares. The Federal Reserve sketched out a cautious outlook of the economy in its last scheduled meeting of the year. The Fed stated that the economic recovery has not been strong enough to reduce the unemployment rate. The Federal Reserve also said ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/12/15/amgn-stock-market-news-for-dec-15-2010-market-news/62397/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(TEVA) Teva Pharmaceutical Industries Beats The Street on Earnings</title>
		<link>http://www.stockbloghub.com/2010/11/15/teva-teva-pharmaceutical-industries-beats-the-street-on-earnings/58457</link>
		<comments>http://www.stockbloghub.com/2010/11/15/teva-teva-pharmaceutical-industries-beats-the-street-on-earnings/58457#comments</comments>
		<pubDate>Mon, 15 Nov 2010 19:00:43 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[MYL]]></category>
		<category><![CDATA[Mylan]]></category>
		<category><![CDATA[TEVA]]></category>
		<category><![CDATA[Teva Pharmaceutical Industries Limited]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=58457</guid>
		<description><![CDATA[Teva Pharmaceutical Industries’ (TEVA) third quarter earnings of $1.30 per American Depository Share (ADS) were above the Zacks Consensus Estimate of $1.27 and the year-ago earnings of 89 cents. Teva’s top-line performance remained strong with revenues increasing 19.7% to $4.3 billion, in-line with the Zacks Consensus Estimate. Contribution from the ratiopharm acquisition, strong sales of Copaxone and generics boosted revenues and helped offset the negative impact of currency fluctuations that hit revenues by $122 million. The Quarter in Detail Revenue performance across key business segments was strong. While Pharmaceutical segment revenues were driven by strong performances in the North American, European and international segments, the Active Pharmaceutical Ingredients (API) segment posted sales of $159 million, up 17%. Pharmaceutical segment revenues were driven by strong performances in the North American, European ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/11/15/teva-teva-pharmaceutical-industries-beats-the-street-on-earnings/58457/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(JNJ) Pharma &amp; Biotech Industry Outlook &#8211; November 2010 &#8211; Industry Outlook</title>
		<link>http://www.stockbloghub.com/2010/11/15/jnj-pharma-biotech-industry-outlook-november-2010-industry-outlook/58687</link>
		<comments>http://www.stockbloghub.com/2010/11/15/jnj-pharma-biotech-industry-outlook-november-2010-industry-outlook/58687#comments</comments>
		<pubDate>Mon, 15 Nov 2010 18:56:40 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[ACL]]></category>
		<category><![CDATA[Alcon Inc]]></category>
		<category><![CDATA[Alkermes]]></category>
		<category><![CDATA[ALKS]]></category>
		<category><![CDATA[AMLN]]></category>
		<category><![CDATA[Amylin Pharmaceuticals Inc]]></category>
		<category><![CDATA[BIIB]]></category>
		<category><![CDATA[Biogen Idec Inc]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[CELG]]></category>
		<category><![CDATA[Celgene Corporation]]></category>
		<category><![CDATA[Charles River Laboratories International Inc]]></category>
		<category><![CDATA[CRL]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[Forest Laboratories Inc.]]></category>
		<category><![CDATA[FRX]]></category>
		<category><![CDATA[GENZ]]></category>
		<category><![CDATA[Genzyme Corporation]]></category>
		<category><![CDATA[GILD]]></category>
		<category><![CDATA[Gilead Sciences Inc]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[KG]]></category>
		<category><![CDATA[King Pharmaceuticals Inc.]]></category>
		<category><![CDATA[LLY]]></category>
		<category><![CDATA[MDCO]]></category>
		<category><![CDATA[Medicines Company]]></category>
		<category><![CDATA[MYL]]></category>
		<category><![CDATA[Mylan]]></category>
		<category><![CDATA[ONXX]]></category>
		<category><![CDATA[Onyx Pharmaceuticals Inc]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>
		<category><![CDATA[VIVUS Inc]]></category>
		<category><![CDATA[VVUS]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=58687</guid>
		<description><![CDATA[With 2010 coming to an end, the pharmaceutical industry continues to witness major challenges like sluggish prescription trends, EU pricing pressure, intensifying generic competition and limited late-stage catalysts. The next five years are expected to reflect a significant imbalance between new product introductions and patent losses. According to IMS Health, this is the main reason global pharmaceutical market growth will be restricted to the mid-single digits (5-8%) through 2014. Over the next five years, products that currently generate more than $142 billion in sales are expected to face generic competition Incorporatedluding Lipitor, Plavix and Zyprexa. In fact, 2011 itself will see products worth more than $30 billion losing patent protection. This includes products like Lipitor, Plavix, Zyprexa and Levaquin. According to IMS Health, these products generated more than $17 billion ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/11/15/jnj-pharma-biotech-industry-outlook-november-2010-industry-outlook/58687/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(CEPH) Cephalon Reports Very Strong Quarterly Earnings</title>
		<link>http://www.stockbloghub.com/2010/11/01/ceph-cephalon-reports-very-strong-quarterly-earnings/57105</link>
		<comments>http://www.stockbloghub.com/2010/11/01/ceph-cephalon-reports-very-strong-quarterly-earnings/57105#comments</comments>
		<pubDate>Mon, 01 Nov 2010 14:16:21 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[CEPH]]></category>
		<category><![CDATA[Cephalon Inc.]]></category>
		<category><![CDATA[CNS]]></category>
		<category><![CDATA[Cohen & Steers Inc.]]></category>
		<category><![CDATA[MYL]]></category>
		<category><![CDATA[Mylan]]></category>
		<category><![CDATA[TEVA]]></category>
		<category><![CDATA[Teva Pharmaceutical Industries Limited]]></category>
		<category><![CDATA[Watson Pharmaceuticals Inc.]]></category>
		<category><![CDATA[WPI]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=57105</guid>
		<description><![CDATA[Cephalon, Inc. (CEPH) delivered another strong quarter with earnings coming at $2.14 per share, easily beating the Zacks Consensus Estimate of $1.79 and well above the year-ago earnings of $1.62. Strong revenues, a favorable product mix and the company’s continuing efforts to improve operating leverage helped Cephalon post impressive results. Revenues increased 30.5% to $716.9 million. However, revenues fell short of the Zacks Consensus Estimate of $719 million. The Quarter in Detail Third quarter revenues consisted of $707.1 million in product sales (up 32%) and $9.9 million in other revenues. Revenues were driven by contributions from the central nervous system (CNS) and oncology franchises, which posted sales of $354.3 million (up 19%) and $132.9 million (up 60%), respectively. Revenues were also boosted by other product sales of $88.8 million, which ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/11/01/ceph-cephalon-reports-very-strong-quarterly-earnings/57105/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(SHPGY) Shire Drug ProAmatine&#8217;s Approval to be Withdrawn by US Food and Drug Administration</title>
		<link>http://www.stockbloghub.com/2010/08/22/shpgy-shire-drug-proamatines-approval-to-be-withdrawn-by-us-food-and-drug-administration/48619</link>
		<comments>http://www.stockbloghub.com/2010/08/22/shpgy-shire-drug-proamatines-approval-to-be-withdrawn-by-us-food-and-drug-administration/48619#comments</comments>
		<pubDate>Sun, 22 Aug 2010 23:28:44 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Impax Laboratories Inc]]></category>
		<category><![CDATA[IPXL]]></category>
		<category><![CDATA[MYL]]></category>
		<category><![CDATA[Mylan]]></category>
		<category><![CDATA[Novartis AG]]></category>
		<category><![CDATA[NVS]]></category>
		<category><![CDATA[Shire Limited]]></category>
		<category><![CDATA[SHPGY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=48619</guid>
		<description><![CDATA[The US Food and Drug Administration (FDA) recently announced that it plans to withdraw the approval of Shire plc’s (SHPGY) ProAmatine. The drug is used to treat low blood pressure (orthostatic hypotension). The drug was approved under the FDA’s accelerated approval program, under which companies are required to conduct post-approval studies of the drug in order to confirm its benefits. The regulatory body noted that since the time of the approval of ProAmatine, neither Shire nor the drug’s generic makers conducted studies that proved the drug’s efficacy in patients suffering from orthostatic hypotension. Shire, in response, issued a press release saying that it had conducted post-approval trials for ProAmatine as required by the FDA, but the regulatory body found those studies inconclusive asking Shire to carry out additional trials to ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/08/22/shpgy-shire-drug-proamatines-approval-to-be-withdrawn-by-us-food-and-drug-administration/48619/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(CEPH) Cephalon Files Lawsuit Against Apotex &#8211; Several Companies Challenging Nuvigil Patent</title>
		<link>http://www.stockbloghub.com/2010/08/21/ceph-cephalon-files-lawsuit-against-apotex-several-companies-challenging-nuvigil-patent/48718</link>
		<comments>http://www.stockbloghub.com/2010/08/21/ceph-cephalon-files-lawsuit-against-apotex-several-companies-challenging-nuvigil-patent/48718#comments</comments>
		<pubDate>Sat, 21 Aug 2010 18:28:23 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[CEPH]]></category>
		<category><![CDATA[Cephalon Inc.]]></category>
		<category><![CDATA[CNS]]></category>
		<category><![CDATA[Cohen & Steers Inc.]]></category>
		<category><![CDATA[EnergySolutions Inc]]></category>
		<category><![CDATA[ES]]></category>
		<category><![CDATA[MYL]]></category>
		<category><![CDATA[Mylan]]></category>
		<category><![CDATA[TEVA]]></category>
		<category><![CDATA[Teva Pharmaceutical Industries Limited]]></category>
		<category><![CDATA[Watson Pharmaceuticals Inc.]]></category>
		<category><![CDATA[WPI]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=48718</guid>
		<description><![CDATA[In a recent filing with the US Securities and Exchange Commission (SEC), Cephalon Inc. (CEPH) announced that it has filed a lawsuit in the US District Court in Delaware against Apotex Corp. and Apotex Inc. Apotex is seeking to launch a generic version of Cephalon’s sleep franchise product, Nuvigil. The lawsuit was filed in response to a Paragraph IV Certification Notice Letter received by Cephalon in July regarding an Abbreviated New Drug Application (ANDA) filed with the US Food and Drug Administration (FDA) by Apotex. The lawsuit has been filed under the provisions of the Hatch-Waxman Act, which means that the FDA cannot grant final approval for up to 30 months or until final resolution of the matter before the court, whichever occurs earlier. Several Companies Challenging Nuvigil Patent We ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/08/21/ceph-cephalon-files-lawsuit-against-apotex-several-companies-challenging-nuvigil-patent/48718/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(CEPH) Cephalon Second Quarter 2010 Earnings Report Beats The Street</title>
		<link>http://www.stockbloghub.com/2010/07/28/ceph-cephalon-second-quarter-2010-earnings-report-beats-the-street/45093</link>
		<comments>http://www.stockbloghub.com/2010/07/28/ceph-cephalon-second-quarter-2010-earnings-report-beats-the-street/45093#comments</comments>
		<pubDate>Wed, 28 Jul 2010 18:55:32 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[BDSI]]></category>
		<category><![CDATA[BioDelivery Sciences International Inc]]></category>
		<category><![CDATA[CEPH]]></category>
		<category><![CDATA[Cephalon Inc.]]></category>
		<category><![CDATA[CNS]]></category>
		<category><![CDATA[Cohen & Steers Inc.]]></category>
		<category><![CDATA[MYL]]></category>
		<category><![CDATA[Mylan]]></category>
		<category><![CDATA[TEVA]]></category>
		<category><![CDATA[Teva Pharmaceutical Industries Limited]]></category>
		<category><![CDATA[Watson Pharmaceuticals Inc.]]></category>
		<category><![CDATA[WPI]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=45093</guid>
		<description><![CDATA[Cephalon Inc. (CEPH) delivered another strong quarter with second quarter earnings coming in at $2.05 per share, six cents above the Zacks Consensus Estimate and well above the year-ago earnings of $1.44 per share. We note that the Zacks Consensus Estimate had been revised recently following Cephalon’s announcement that it expects to deliver second quarter earnings above its previously issued guidance. Strong revenues helped the company post impressive results. Revenue increased 32.7% to $726.9 million, exceeding the Zacks Consensus Estimate by almost $19 million. The Mepha acquisition contributed $90 million to second-quarter revenue. The Quarter in Detail Second-quarter revenue consisted of $712.4 million in product sales (up 32.2%) and $14.5 million in other revenue. Revenue was driven by contributions from the central nervous system (CNS) and oncology franchises, which posted ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/07/28/ceph-cephalon-second-quarter-2010-earnings-report-beats-the-street/45093/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(TEVA) Teva Pharmaceutical Industries Second Quarter 2010 Earnings Tops Estimates</title>
		<link>http://www.stockbloghub.com/2010/07/28/teva-teva-pharmaceutical-industries-second-quarter-2010-earnings-tops-estimates/45009</link>
		<comments>http://www.stockbloghub.com/2010/07/28/teva-teva-pharmaceutical-industries-second-quarter-2010-earnings-tops-estimates/45009#comments</comments>
		<pubDate>Wed, 28 Jul 2010 14:36:59 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[MYL]]></category>
		<category><![CDATA[Mylan]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>
		<category><![CDATA[TEVA]]></category>
		<category><![CDATA[Teva Pharmaceutical Industries Limited]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=45009</guid>
		<description><![CDATA[Teva Pharmaceutical Industries’ (TEVA) second quarter earnings of $1.08 per American Depository Share (ADS) was above the Zacks Consensus Estimate of $1.04 and the year-ago earnings of 83 cents. Teva’s top-line performance remained strong with revenues increasing 11.8% to $3.8 billion, in-line with the Zacks Consensus Estimate. Strong sales of Copaxone and generics helped drive revenues. Quarterly Details Revenue performance across key business segments was strong. While Pharmaceutical segment revenues were driven by strong performances in the North American, European and international segments, the active pharmaceutical ingredients (API) segment posted sales of $135 million, up 21%. Pharmaceutical segment revenues were driven by strong performances in the North American, European and International segments. The launch of generic versions of Hyzaar, Cozaar and Yaz and continued strong sales from existing products like ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/07/28/teva-teva-pharmaceutical-industries-second-quarter-2010-earnings-tops-estimates/45009/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(CEPH) Cephalon Second Quarter 2010 Earnings Preview</title>
		<link>http://www.stockbloghub.com/2010/07/27/ceph-cephalon-second-quarter-2010-earnings-preview/44914</link>
		<comments>http://www.stockbloghub.com/2010/07/27/ceph-cephalon-second-quarter-2010-earnings-preview/44914#comments</comments>
		<pubDate>Tue, 27 Jul 2010 13:28:43 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[CEPH]]></category>
		<category><![CDATA[Cephalon Inc.]]></category>
		<category><![CDATA[CNS]]></category>
		<category><![CDATA[Cohen & Steers Inc.]]></category>
		<category><![CDATA[MYL]]></category>
		<category><![CDATA[Mylan]]></category>
		<category><![CDATA[TEVA]]></category>
		<category><![CDATA[Teva Pharmaceutical Industries Limited]]></category>
		<category><![CDATA[Watson Pharmaceuticals Inc.]]></category>
		<category><![CDATA[WPI]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=44914</guid>
		<description><![CDATA[Cephalon Inc. (CEPH) is scheduled to report second quarter results on July 27, 2010 after the market closes. The current Zacks Consensus Estimate for the second quarter is $1.99 per diluted share, representing year-over-year growth of 38%. Cephalon has consistently surpassed earnings estimates with a four-quarter average of 10.1%, and second quarter earnings are also expected to top expectations by 4.5%. Last week, Cephalon revised its guidance for the quarter saying that it now expects basic adjusted income per common share in the range of $2.17-$2.22 on sales of $705million-$715 million. Earlier, Cephalon was expecting basic adjusted income of $1.65-$1.75 per share on net sales of $645 &#8211; $670 million. The Zacks Consensus Revenue Estimate is $708 million. Based on the revised expectations for the second quarter, Cephalon will also ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/07/27/ceph-cephalon-second-quarter-2010-earnings-preview/44914/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(FRX) Forest Laboratories Settles Patent Fight</title>
		<link>http://www.stockbloghub.com/2010/07/26/frx-forest-laboratories-settles-patent-fight/44919</link>
		<comments>http://www.stockbloghub.com/2010/07/26/frx-forest-laboratories-settles-patent-fight/44919#comments</comments>
		<pubDate>Mon, 26 Jul 2010 21:35:42 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Dr. Reddy's Laboratories Limited]]></category>
		<category><![CDATA[Forest Laboratories Inc.]]></category>
		<category><![CDATA[FRX]]></category>
		<category><![CDATA[MYL]]></category>
		<category><![CDATA[Mylan]]></category>
		<category><![CDATA[RDY]]></category>
		<category><![CDATA[TEVA]]></category>
		<category><![CDATA[Teva Pharmaceutical Industries Limited]]></category>
		<category><![CDATA[Watson Pharmaceuticals Inc.]]></category>
		<category><![CDATA[WPI]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=44919</guid>
		<description><![CDATA[Forest Laboratories Inc. (FRX) and partner Merz GmbH &#38; Co. KGaA recently entered into a patent litigation settlement agreement with about 10 companies that were seeking to launch their generic versions of Alzheimer&#8217;s drug Namenda (memantine). As per the settlement agreement, the generic version of the drug will enter the market on January 11, 2015, three months before the patent expires in April 2010. This settlement agreement is subject to review by the US government. While Forest Labs and Merz settled the litigation with Watson Pharmaceuticals Inc. (WPI), Dr. Reddy&#8217;s Laboratories Ltd. (RDY), Mylan Inc. (MYL), Teva Pharmaceutical Industries Ltd. (TEVA) and a few other companies, the dispute is still ongoing with certain other generic manufacturers. We believe Forest Labs and Merz will seek to settle with these companies as ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/07/26/frx-forest-laboratories-settles-patent-fight/44919/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ABT) Pharma and Biotech Industry Outlook &#8211; July 2010 &#8211; Analyst Interviews</title>
		<link>http://www.stockbloghub.com/2010/07/26/abt-pharma-and-biotech-industry-outlook-july-2010-analyst-interviews/44204</link>
		<comments>http://www.stockbloghub.com/2010/07/26/abt-pharma-and-biotech-industry-outlook-july-2010-analyst-interviews/44204#comments</comments>
		<pubDate>Mon, 26 Jul 2010 14:58:05 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[ABC]]></category>
		<category><![CDATA[ABII]]></category>
		<category><![CDATA[Abraxis Bioscience Inc]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[ACL]]></category>
		<category><![CDATA[ACOR]]></category>
		<category><![CDATA[Acorda Therapeutics Inc]]></category>
		<category><![CDATA[Alcon Inc]]></category>
		<category><![CDATA[Alkermes]]></category>
		<category><![CDATA[ALKS]]></category>
		<category><![CDATA[AmerisourceBergen Corporation]]></category>
		<category><![CDATA[AMLN]]></category>
		<category><![CDATA[Amylin Pharmaceuticals Inc]]></category>
		<category><![CDATA[BIIB]]></category>
		<category><![CDATA[Biogen Idec Inc]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[CELG]]></category>
		<category><![CDATA[Celgene Corporation]]></category>
		<category><![CDATA[Charles River Laboratories International Inc]]></category>
		<category><![CDATA[CRL]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[Forest Laboratories Inc.]]></category>
		<category><![CDATA[FRX]]></category>
		<category><![CDATA[GENZ]]></category>
		<category><![CDATA[Genzyme Corporation]]></category>
		<category><![CDATA[GILD]]></category>
		<category><![CDATA[Gilead Sciences Inc]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[LLY]]></category>
		<category><![CDATA[MDCO]]></category>
		<category><![CDATA[Medicines Company]]></category>
		<category><![CDATA[Merck & Company Inc]]></category>
		<category><![CDATA[MRK]]></category>
		<category><![CDATA[MYL]]></category>
		<category><![CDATA[Mylan]]></category>
		<category><![CDATA[ONXX]]></category>
		<category><![CDATA[Onyx Pharmaceuticals Inc]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=44204</guid>
		<description><![CDATA[The pharmaceutical industry has witnessed major changes over the past few quarters, with performance being affected by factors like sluggish prescription trends, intensifying generic competition and limited late-stage catalysts. The next five years are expected to reflect a significant imbalance between new product introductions and patent losses. According to IMS Health, this is the main reason global pharmaceutical market growth will be restricted to the mid-single digits (5-8%) through 2014. Over the next five years, products that currently generate more than $142 billion in sales are expected to face generic competition Incorporatedluding Lipitor, Plavix and Zyprexa. At the same time, new products are not expected to generate the same level of sales as products losing patent protection. With revenue growth stalling or slowing down, companies have been resorting to cost-cutting ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/07/26/abt-pharma-and-biotech-industry-outlook-july-2010-analyst-interviews/44204/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ABT) Pharma and Biotech Industry Outlook &#8211; July 2010 &#8211; Industry Outlook</title>
		<link>http://www.stockbloghub.com/2010/07/20/abt-pharma-and-biotech-industry-outlook-july-2010-industry-outlook/44146</link>
		<comments>http://www.stockbloghub.com/2010/07/20/abt-pharma-and-biotech-industry-outlook-july-2010-industry-outlook/44146#comments</comments>
		<pubDate>Wed, 21 Jul 2010 03:08:56 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[ABC]]></category>
		<category><![CDATA[ABII]]></category>
		<category><![CDATA[Abraxis Bioscience Inc]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[ACL]]></category>
		<category><![CDATA[ACOR]]></category>
		<category><![CDATA[Acorda Therapeutics Inc]]></category>
		<category><![CDATA[Alcon Inc]]></category>
		<category><![CDATA[Alkermes]]></category>
		<category><![CDATA[ALKS]]></category>
		<category><![CDATA[AmerisourceBergen Corporation]]></category>
		<category><![CDATA[AMLN]]></category>
		<category><![CDATA[Amylin Pharmaceuticals Inc]]></category>
		<category><![CDATA[BIIB]]></category>
		<category><![CDATA[Biogen Idec Inc]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[CELG]]></category>
		<category><![CDATA[Celgene Corporation]]></category>
		<category><![CDATA[Charles River Laboratories International Inc]]></category>
		<category><![CDATA[CRL]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[Forest Laboratories Inc.]]></category>
		<category><![CDATA[FRX]]></category>
		<category><![CDATA[GENZ]]></category>
		<category><![CDATA[Genzyme Corporation]]></category>
		<category><![CDATA[GILD]]></category>
		<category><![CDATA[Gilead Sciences Inc]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[Inc.]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[LLY]]></category>
		<category><![CDATA[MDCO]]></category>
		<category><![CDATA[Medicines Company]]></category>
		<category><![CDATA[Merck & Company Inc]]></category>
		<category><![CDATA[MRK]]></category>
		<category><![CDATA[MYL]]></category>
		<category><![CDATA[Mylan]]></category>
		<category><![CDATA[ONXX]]></category>
		<category><![CDATA[Onyx Pharmaceuticals Inc]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=44146</guid>
		<description><![CDATA[The pharmaceutical industry has witnessed major changes over the past few quarters, with performance being affected by factors like sluggish prescription trends, intensifying generic competition and limited late-stage catalysts. The next five years are expected to reflect a significant imbalance between new product introductions and patent losses. According to IMS Health, this is the main reason global pharmaceutical market growth will be restricted to the mid-single digits (5-8%) through 2014. Over the next five years, products that currently generate more than $142 billion in sales are expected to face generic competition Incorporatedluding Lipitor, Plavix and Zyprexa. At the same time, new products are not expected to generate the same level of sales as products losing patent protection. With revenue growth stalling or slowing down, companies have been resorting to cost-cutting ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/07/20/abt-pharma-and-biotech-industry-outlook-july-2010-industry-outlook/44146/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(MYL) Mylan Earns FDA Approval for Generic Version of Valtrex</title>
		<link>http://www.stockbloghub.com/2010/05/30/myl-mylan-earns-fda-approval-for-generic-version-of-valtrex/38900</link>
		<comments>http://www.stockbloghub.com/2010/05/30/myl-mylan-earns-fda-approval-for-generic-version-of-valtrex/38900#comments</comments>
		<pubDate>Sun, 30 May 2010 17:11:58 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drugs - Generic]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[Inc.]]></category>
		<category><![CDATA[MYL]]></category>
		<category><![CDATA[Mylan]]></category>
		<category><![CDATA[Novartis AG]]></category>
		<category><![CDATA[NVS]]></category>
		<category><![CDATA[TEVA]]></category>
		<category><![CDATA[Teva Pharmaceutical Industries Limited]]></category>
		<category><![CDATA[Watson Pharmaceuticals Inc.]]></category>
		<category><![CDATA[WPI]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=38900</guid>
		<description><![CDATA[Recently, Mylan Inc. (MYL) received approval from the US Food and Drug Administration (FDA) for its generic version of GlaxoSmithKline’s (GSK) Valtrex, a treatment for herpes virus infection. The drug recorded US sales of about $2.15 billion in 2009 for the twelve months ending March 2010. Apart from Mylan, Teva Pharmaceuticals (TEVA), Watson Pharma (WPI) and Sandoz, the generic arm of Novartis (NVS) have also received approval. Following the approval of Valtrex, Mylan’s generic portfolio will become stronger. In the past few months, Mylan has received many significant approvals. These include the generic versions of Glaxo’s smoking cessation aid, Zyban; Boehringer Ingelheim&#8217;s benign prostatic hyperplasia (BPH) treatment, Flomax and Lundbeck’s Desoxyn. Mylan received a significant approval in the field of HIV treatment for its subsidiary, Matrix. The company has received ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/05/30/myl-mylan-earns-fda-approval-for-generic-version-of-valtrex/38900/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(MYL) Mylan First Quarter 2010 Earnings Scorecard</title>
		<link>http://www.stockbloghub.com/2010/05/24/myl-mylan-first-quarter-2010-earnings-scorecard/37661</link>
		<comments>http://www.stockbloghub.com/2010/05/24/myl-mylan-first-quarter-2010-earnings-scorecard/37661#comments</comments>
		<pubDate>Mon, 24 May 2010 21:27:15 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drugs - Generic]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[MYL]]></category>
		<category><![CDATA[Mylan]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=37661</guid>
		<description><![CDATA[First Quarter Highlights On April 29, Mylan (MYL) reported first quarter fiscal 2010 earnings per share (EPS) of 20 cents, down from the year-ago earnings of 23 cents. On an adjusted basis, first quarter earnings came in at 36 cents, a couple of cents above the Zacks Consensus Estimate and well above the year-ago earnings of 33 cents. Revenues increased 7% to $1.29 billion, mainly due to a positive foreign exchange (FX) impact. Excluding the favorable FX impact, revenues would have increased 2%. Mylan reiterated its guidance for 2010. The EPS is expected in the range of $1.50 to $1.70 and the company expects to generate total revenues of $5.45 to $5.75 billion. Agreement of Analysts Following the release of first quarter results, estimate revision trends among the analysts depict ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/05/24/myl-mylan-first-quarter-2010-earnings-scorecard/37661/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(TEVA) Teva Pharmaceutical Industries Reports Earnings That Beat The Street</title>
		<link>http://www.stockbloghub.com/2010/05/12/teva-teva-pharmaceutical-industries-reports-earnings-that-beat-the-street/36982</link>
		<comments>http://www.stockbloghub.com/2010/05/12/teva-teva-pharmaceutical-industries-reports-earnings-that-beat-the-street/36982#comments</comments>
		<pubDate>Wed, 12 May 2010 21:29:23 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[ADS]]></category>
		<category><![CDATA[Advanced Photonix Inc.]]></category>
		<category><![CDATA[Alliance Data Systems Corporation]]></category>
		<category><![CDATA[API]]></category>
		<category><![CDATA[MYL]]></category>
		<category><![CDATA[Mylan]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>
		<category><![CDATA[TEVA]]></category>
		<category><![CDATA[Teva Pharmaceutical Industries Limited]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=36982</guid>
		<description><![CDATA[Teva Pharmaceutical Industries’ (TEVA) first quarter earnings of 91 cents per American Depository Share (ADS) was well above the Zacks Consensus Estimate of 89 cents and the year-ago earnings of 71 cents. Teva’s top-line performance remained strong with revenues increasing 16% to $3.7 billion. Strong sales of Copaxone and generics helped drive revenues. The Quarter in Detail Revenue performance across key business segments was mixed. While the Pharmaceuticals segment performed well thanks to strong performances in the North American, European and international segments, the Active Pharmaceutical Ingredients (API) segment reported a 13.7% decline in growth with sales coming in at $139 million. Pharmaceutical segment revenues were driven by strong performances in the North American, European and international segments. The launch of a generic version of Mirapex and continued strong sales ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/05/12/teva-teva-pharmaceutical-industries-reports-earnings-that-beat-the-street/36982/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(MYL) Mylan&#8217;s Quarterly Earnings Tops Expectations</title>
		<link>http://www.stockbloghub.com/2010/04/29/myl-mylans-quarterly-earnings-tops-expectations/35671</link>
		<comments>http://www.stockbloghub.com/2010/04/29/myl-mylans-quarterly-earnings-tops-expectations/35671#comments</comments>
		<pubDate>Fri, 30 Apr 2010 00:15:29 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drugs - Generic]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[MYL]]></category>
		<category><![CDATA[Mylan]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=35671</guid>
		<description><![CDATA[Mylan (MYL) reported first quarter earnings per share of 20 cents, down from the year-ago earnings of 23 cents. On an adjusted basis, first quarter 2010 earnings came in at 36 cents, a couple of cents above the Zacks Consensus Estimate and well above the year-ago earnings of 33 cents. Revenues increased 7% to $1.29 billion, mainly due to a positive foreign exchange (FX) impact. Excluding the favorable FX impact, revenues would have increased 2% to $20.6 million. Both revenue segments at Mylan recorded growth during the first quarter. While Generics accounted for about 96% of total first quarter revenues, posting sales of $1.24 billion (up 7.8%), revenues from the Specialty segment increased 20.7% to $101 million. Specialty revenues were driven by higher sales of Dey&#8217;s EpiPen Auto-Injector, Perforomist Solution, ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/04/29/myl-mylans-quarterly-earnings-tops-expectations/35671/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ABT) Pharma &amp; Biotech Stock Review &#8211; April 2010 &#8211; Industry Outlook</title>
		<link>http://www.stockbloghub.com/2010/04/29/abt-pharma-biotech-stock-review-april-2010-industry-outlook/35472</link>
		<comments>http://www.stockbloghub.com/2010/04/29/abt-pharma-biotech-stock-review-april-2010-industry-outlook/35472#comments</comments>
		<pubDate>Thu, 29 Apr 2010 14:10:15 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[ACL]]></category>
		<category><![CDATA[ACOR]]></category>
		<category><![CDATA[Acorda Therapeutics Inc]]></category>
		<category><![CDATA[Alcon Inc]]></category>
		<category><![CDATA[Amgen Inc]]></category>
		<category><![CDATA[AMGN]]></category>
		<category><![CDATA[BIIB]]></category>
		<category><![CDATA[Biogen Idec Inc]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[Forest Laboratories Inc.]]></category>
		<category><![CDATA[FRX]]></category>
		<category><![CDATA[GENZ]]></category>
		<category><![CDATA[Genzyme Corporation]]></category>
		<category><![CDATA[GILD]]></category>
		<category><![CDATA[Gilead Sciences Inc]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[Inc.]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[LLY]]></category>
		<category><![CDATA[MannKind Corporation]]></category>
		<category><![CDATA[MDCO]]></category>
		<category><![CDATA[Medicines Company]]></category>
		<category><![CDATA[Merck & Company Inc]]></category>
		<category><![CDATA[MIL]]></category>
		<category><![CDATA[Millipore Corporation]]></category>
		<category><![CDATA[MNKD]]></category>
		<category><![CDATA[MRK]]></category>
		<category><![CDATA[MYL]]></category>
		<category><![CDATA[Mylan]]></category>
		<category><![CDATA[OSI Pharmaceuticals Inc]]></category>
		<category><![CDATA[OSIP]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=35472</guid>
		<description><![CDATA[The pharmaceutical industry has witnessed major changes over the past few quarters, with performance being affected by factors like sluggish prescription trends, intensifying generic competition and limited phase III catalysts. The next five years are expected to reflect a significant imbalance between new product introductions and patent losses. According to IMS Health, this is the main reason global pharmaceutical market growth will be restricted to the mid-single digits (5-8%) through 2014. Over the next five years, products that currently generate more than $142 billion in sales are expected to face generic competition Incorporatedluding Lipitor, Plavix and Zyprexa. At the same time, new products are not expected to generate the same level of sales as products losing patent protection. With revenue growth stalling or slowing down, companies have been resorting to ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/04/29/abt-pharma-biotech-stock-review-april-2010-industry-outlook/35472/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(CEPH) Cephalon Completes Aquisition of Generic Drug Company Mepha AG</title>
		<link>http://www.stockbloghub.com/2010/04/12/ceph-cephalon-completes-aquisition-of-generic-drug-company-mepha-ag/33501</link>
		<comments>http://www.stockbloghub.com/2010/04/12/ceph-cephalon-completes-aquisition-of-generic-drug-company-mepha-ag/33501#comments</comments>
		<pubDate>Tue, 13 Apr 2010 03:39:43 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[CEPH]]></category>
		<category><![CDATA[Cephalon Inc.]]></category>
		<category><![CDATA[MYL]]></category>
		<category><![CDATA[Mylan]]></category>
		<category><![CDATA[TEVA]]></category>
		<category><![CDATA[Teva Pharmaceutical Industries Limited]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=33501</guid>
		<description><![CDATA[Cephalon, Inc. (CEPH) recently announced the completion of its acquisition of Mepha AG, a privately-held Swiss generic drug company, for CHF 662.4 million (approximately $615.4 million). This acquisition marks Cephalon’s entry in the generics market. This deal is in-line with Cephalon’s goal to reduce its dependence on its central nervous system (CNS) franchise for long-term growth. The company’s CNS franchise, which consists of Nuvigil, Provigil and Gabitril, is its primary growth driver. However, Provigil is slated to face generic competition from 2012 and Nuvigil is facing patent challenges from generic players like Teva (TEVA) and Mylan (MYL). As such, Cephalon is looking to supplement long-term growth by acquiring/in-licensing products. The Mepha acquisition will not only allow Cephalon to enter the generic drug market, it will also allow the company to ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/04/12/ceph-cephalon-completes-aquisition-of-generic-drug-company-mepha-ag/33501/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(MYL) Mylan Earns FDA Approval For Laxative Candidate</title>
		<link>http://www.stockbloghub.com/2010/04/08/myl-mylan-earns-fda-approval-for-laxative-candidate/33214</link>
		<comments>http://www.stockbloghub.com/2010/04/08/myl-mylan-earns-fda-approval-for-laxative-candidate/33214#comments</comments>
		<pubDate>Thu, 08 Apr 2010 21:19:50 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drugs - Generic]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[MYL]]></category>
		<category><![CDATA[Mylan]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=33214</guid>
		<description><![CDATA[Mylan Inc. (MYL) received approval from the US Food and Drug Administration (FDA) for the generic version of Braintree Laboratories&#8217; NuLytely, a laxative. The company is eligible to ship the product immediately, which recorded US sales of about $31 million in 2009. Following this approval, Mylan’s generic portfolio will be strengthened further. We are also happy to note that in March 2010, the company had entered into an agreement with Takeda Pharmaceutical for two type II diabetes drugs &#8212; Actoplus Met and Actos &#8212; which recorded 2009 sales of $459 million and $3.4 billion, respectively. Mylan has received quite a few significant approvals in 2009 including the generic version of Bristol-Myers Squibb&#8217;s (BMY) Sinemet for treating Parkinson’s and Takeda Pharmaceuticals&#8217; proton pump inhibitor Prevacid delayed-release (DR) capsules. The company has ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/04/08/myl-mylan-earns-fda-approval-for-laxative-candidate/33214/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(CEPH) Cephalon Experiences Regulatory Setback</title>
		<link>http://www.stockbloghub.com/2010/03/31/ceph-cephalon-experiences-regulatory-setback/32392</link>
		<comments>http://www.stockbloghub.com/2010/03/31/ceph-cephalon-experiences-regulatory-setback/32392#comments</comments>
		<pubDate>Wed, 31 Mar 2010 20:13:29 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[CEPH]]></category>
		<category><![CDATA[Cephalon Inc.]]></category>
		<category><![CDATA[MYL]]></category>
		<category><![CDATA[Mylan]]></category>
		<category><![CDATA[TEVA]]></category>
		<category><![CDATA[Teva Pharmaceutical Industries Limited]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=32392</guid>
		<description><![CDATA[Cephalon, Inc. (CEPH) suffered a regulatory setback recently with its failure to receive outright approval from the US Food and Drug Administration (FDA) for its supplemental new drug application (sNDA) for Nuvigil. Cephalon was seeking to get Nuvigil approved for the treatment of patients with excessive sleepiness associated with jet lag disorder resulting from eastbound travel. Cephalon had submitted data from a study that was conducted under the FDA’s special protocol assessment process. The company had evaluated the efficacy of the drug based on two primary endpoints: an objective assessment (the Multiple Sleep Latency Test), and a subjective assessment (the Patient Global Impression of Severity). Even though Nuvigil achieved statistical significance in both endpoints, the FDA has raised questions in its complete response letter regarding the strength of the subjective ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/03/31/ceph-cephalon-experiences-regulatory-setback/32392/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(TEVA) Teva Pharmaceutical Industries Wins Race for Ratiopharm</title>
		<link>http://www.stockbloghub.com/2010/03/19/teva-teva-pharmaceutical-industries-wins-race-for-ratiopharm/31301</link>
		<comments>http://www.stockbloghub.com/2010/03/19/teva-teva-pharmaceutical-industries-wins-race-for-ratiopharm/31301#comments</comments>
		<pubDate>Fri, 19 Mar 2010 21:53:47 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[MYL]]></category>
		<category><![CDATA[Mylan]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[TEVA]]></category>
		<category><![CDATA[Teva Pharmaceutical Industries Limited]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=31301</guid>
		<description><![CDATA[Teva Pharmaceutical Industries Ltd. (TEVA) recently announced its second major acquisition in a span of two years. The company announced its intention to acquire Germany’s second largest generics producer, ratiopharm, for an enterprise value of €3.625 billion or approximately $5 billion. Teva’s last major acquisition was that of Barr Pharmaceuticals, a US-based multinational generic pharmaceutical company with operations mainly in the US and Europe. This acquisition boosted Teva’s product portfolio which now includes several generic pharmaceutical products as well as women’s health products. Teva reportedly beat pharmaceutical giant, Pfizer, Inc. (PFE) and Actavis Group, to win the race for ratiopharm. Teva is no stranger to acquisitions. In addition to the Barr and ratiopharm acquisitions, other major acquisitions in Teva’s history include those of Ivax Corp. (Jan 2006) and Sicor Inc. ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/03/19/teva-teva-pharmaceutical-industries-wins-race-for-ratiopharm/31301/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(MYL) Mylan Strengthens Drug Portfolio</title>
		<link>http://www.stockbloghub.com/2010/03/17/myl-mylan-strengthens-drug-portfolio/30934</link>
		<comments>http://www.stockbloghub.com/2010/03/17/myl-mylan-strengthens-drug-portfolio/30934#comments</comments>
		<pubDate>Wed, 17 Mar 2010 22:27:36 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drugs - Generic]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[MYL]]></category>
		<category><![CDATA[Mylan]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=30934</guid>
		<description><![CDATA[Mylan Inc. (MYL) has entered into an agreement with Takeda Pharmaceutical for two type II diabetes drugs – Actoplus Met and Actos, which recorded 2009 sales of $459 million and $3.4 billion, respectively. Following the agreement, Mylan will be able to launch the generic versions of Actoplus Met on Dec 14, 2012 and Actos on Aug 17, 2012 or earlier under certain circumstances. The company expects to be eligible for 180 days of marketing exclusivity for both the drugs on approval. Mylan has received quite a few significant approvals in 2009 including for the generic version of Bristol-Myers Squibb&#8217;s (BMY) Sinemet for treating Parkinson’s and Takeda Pharmaceuticals&#8217; proton pump inhibitor Prevacid delayed-release (DR) capsules. The company also settled its dispute with Pfizer (PFE) related to antifungal drug Vfend (voriconazole), following ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/03/17/myl-mylan-strengthens-drug-portfolio/30934/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(SLXP) Salix Pharmaceuticals Focuses on Label Expansion</title>
		<link>http://www.stockbloghub.com/2010/03/08/slxp-salix-pharmaceuticals-focuses-on-label-expansion/29955</link>
		<comments>http://www.stockbloghub.com/2010/03/08/slxp-salix-pharmaceuticals-focuses-on-label-expansion/29955#comments</comments>
		<pubDate>Mon, 08 Mar 2010 15:52:43 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Related Products]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[MYL]]></category>
		<category><![CDATA[Mylan]]></category>
		<category><![CDATA[Salix Pharmaceuticals Limited]]></category>
		<category><![CDATA[SLXP]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=29955</guid>
		<description><![CDATA[Salix Pharmaceuticals, Ltd. (SLXP) is slated to report fourth quarter as well as fiscal 2009 results on March 9. The current Zacks Consensus Estimate for the fourth quarter of 2009 is a loss of 14 cents. For the full year, the Zacks Consensus Estimate stands at a loss of 89 cents. Salix suffered a major setback in Dec 2007 when its lead product, Colazal, started facing generics from several companies including Mylan (MYL). The genericization of Colazal adversely impacted the company’s top-and bottom-line. Since then, Salix has been working on reviving growth and is now focusing on gaining additional indications for its current growth driver, Xifaxan (rifaximin). More than earnings, we believe that investor focus will remain on the company’s success in gaining approval for additional indications of Xifaxan. Salix ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/03/08/slxp-salix-pharmaceuticals-focuses-on-label-expansion/29955/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>($MYL) Mylan Beats Earnings Expectations &#8211; Outlook Robust</title>
		<link>http://www.stockbloghub.com/2010/02/25/myl-mylan-beats-earnings-expectations-outlook-robust/29055</link>
		<comments>http://www.stockbloghub.com/2010/02/25/myl-mylan-beats-earnings-expectations-outlook-robust/29055#comments</comments>
		<pubDate>Thu, 25 Feb 2010 20:47:32 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drugs - Generic]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[MYL]]></category>
		<category><![CDATA[Mylan]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=29055</guid>
		<description><![CDATA[Mylan (MYL) reported fourth quarter earnings per share (EPS) of 33 cents, surpassing the Zacks Consensus Estimate of 30 cents and 26 cents in the prior-year period. For the full year 2009, EPS came in at $1.30, up 62.5% from 80 cents in 2008. Mylan reported revenues of $1.35 billion, a 12% increase compared to $1.20 billion in the year-ago period. Revenues were favorably impacted by the foreign currency translation. For the full year, the company recorded $5.09 billion in sales, marginally lower than $5.14 billion in the previous year, which included $468.1 million of previously deferred revenue related to its sale of Bystolic rights. From the third quarter of 2009, Mylan has decided to report its results in two segments &#8212; Generics and Specialty &#8212; following the acquisition of ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/02/25/myl-mylan-beats-earnings-expectations-outlook-robust/29055/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(TEVA) Teva Pharmaceutical Industries Misses Earnings by a Penny</title>
		<link>http://www.stockbloghub.com/2010/02/17/teva-teva-pharmaceutical-industries-misses-earnings-by-a-penny/28240</link>
		<comments>http://www.stockbloghub.com/2010/02/17/teva-teva-pharmaceutical-industries-misses-earnings-by-a-penny/28240#comments</comments>
		<pubDate>Wed, 17 Feb 2010 22:49:18 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[ADS]]></category>
		<category><![CDATA[Advanced Photonix Inc.]]></category>
		<category><![CDATA[Alliance Data Systems Corporation]]></category>
		<category><![CDATA[API]]></category>
		<category><![CDATA[MYL]]></category>
		<category><![CDATA[Mylan]]></category>
		<category><![CDATA[TEVA]]></category>
		<category><![CDATA[Teva Pharmaceutical Industries Limited]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=28240</guid>
		<description><![CDATA[Teva Pharmaceutical Industries’ (TEVA) fourth quarter earnings of 94 cents per American Depository Share (ADS) missed the Zacks Consensus Estimate by a cent. Earnings, however Incorporatedreased 18% from the year-ago period. Annual earnings were in line with the Zacks Consensus Estimate at $3.37 per ADS, up 11%. Teva’s top-line performance remained strong with fourth quarter revenues increasing 33% to $3.8 billion and 2009 revenues coming in at $13.9 billion, up 25%. The strong top-line performance was offset by higher operating expenses which led to the earnings miss in the fourth quarter. Fourth Quarter in Detail Strong sales of Copaxone and the respiratory business helped drive revenues in the reported quarter. Net revenues increased 33% to $3.80 billion, with the Barr acquisition contributing to revenues across different geographical segments. Exchange rate ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/02/17/teva-teva-pharmaceutical-industries-misses-earnings-by-a-penny/28240/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(TEVA) Teva Pharmaceutical Industries Ltd Amends Agreement</title>
		<link>http://www.stockbloghub.com/2010/02/16/teva-teva-pharmaceutical-industries-ltd-amends-agreement/28166</link>
		<comments>http://www.stockbloghub.com/2010/02/16/teva-teva-pharmaceutical-industries-ltd-amends-agreement/28166#comments</comments>
		<pubDate>Wed, 17 Feb 2010 00:08:18 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[MYL]]></category>
		<category><![CDATA[Mylan]]></category>
		<category><![CDATA[TEVA]]></category>
		<category><![CDATA[Teva Pharmaceutical Industries Limited]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=28166</guid>
		<description><![CDATA[Teva Pharmaceutical Industries Ltd. (TEVA) recently amended its marketing and distribution agreement with Active Biotech for oral laquinimod, which is being developed for the treatment of relapsing-remitting multiple sclerosis (RRMS). Teva had initially acquired exclusive rights to develop, register, manufacture and commercialize laquinimod worldwide, except for the Nordic and Baltic countries. As per the terms of the amended agreement, Teva will now have marketing and distribution rights in the Nordic and Baltic regions as well. As a result of the amendment, Active Biotech is entitled to receive a higher royalty rate on sales in these regions compared to the royalty rate fixed in the original agreement that was signed in June 2004. Laquinimod is the lead pipeline candidate at Teva. The phase III candidate received fast track designation in the ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/02/16/teva-teva-pharmaceutical-industries-ltd-amends-agreement/28166/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(CEPH) Cephalon Enters Generics Market</title>
		<link>http://www.stockbloghub.com/2010/02/02/ceph-cephalon-enters-generics-market/26804</link>
		<comments>http://www.stockbloghub.com/2010/02/02/ceph-cephalon-enters-generics-market/26804#comments</comments>
		<pubDate>Wed, 03 Feb 2010 01:07:23 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[CEPH]]></category>
		<category><![CDATA[Cephalon Inc.]]></category>
		<category><![CDATA[MYL]]></category>
		<category><![CDATA[Mylan]]></category>
		<category><![CDATA[TEVA]]></category>
		<category><![CDATA[Teva Pharmaceutical Industries Limited]]></category>
		<category><![CDATA[Watson Pharmaceuticals Inc.]]></category>
		<category><![CDATA[WPI]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=26804</guid>
		<description><![CDATA[Cephalon Inc. (CEPH) has recently signed a deal which should mark the company’s entry into the generics business. The company announced that it intends to acquire Mepha AG, a privately held Swiss generic drug company for approximately $590 million (CHF 622.5 million). This deal is in-line with Cephalon’s goal to reduce its dependence on its central nervous system (CNS) franchise for long-term growth. The company’s CNS franchise, which consists of Nuvigil, Provigil and Gabitril, is its primary growth driver. However, Provigil is slated to face generic competition from 2012 and Nuvigil is facing patent challenges from generic players such as Teva (TEVA), Watson Pharmaceuticals (WPI) and Mylan (MYL). Given this scenario, Cephalon is looking to supplement long-term growth by acquiring/in-licensing products. The Mepha acquisition will not only allow Cephalon to ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/02/02/ceph-cephalon-enters-generics-market/26804/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(RX) Pharma &amp; Biotech Stock Review &#8211; Industry Outlook</title>
		<link>http://www.stockbloghub.com/2010/01/29/rx-pharma-biotech-stock-review-industry-outlook/26385</link>
		<comments>http://www.stockbloghub.com/2010/01/29/rx-pharma-biotech-stock-review-industry-outlook/26385#comments</comments>
		<pubDate>Sat, 30 Jan 2010 00:08:31 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Research Services]]></category>
		<category><![CDATA[Services]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[ACL]]></category>
		<category><![CDATA[ACOR]]></category>
		<category><![CDATA[Acorda Therapeutics Inc]]></category>
		<category><![CDATA[Alcon Inc]]></category>
		<category><![CDATA[Alkermes]]></category>
		<category><![CDATA[ALKS]]></category>
		<category><![CDATA[BIIB]]></category>
		<category><![CDATA[Biogen Idec Inc]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[GENZ]]></category>
		<category><![CDATA[Genzyme Corporation]]></category>
		<category><![CDATA[GILD]]></category>
		<category><![CDATA[Gilead Sciences Inc]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[IMS Health Inc.]]></category>
		<category><![CDATA[Inc.]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[LLY]]></category>
		<category><![CDATA[MannKind Corporation]]></category>
		<category><![CDATA[MDCO]]></category>
		<category><![CDATA[Medicines Company]]></category>
		<category><![CDATA[Merck & Company Inc]]></category>
		<category><![CDATA[MNKD]]></category>
		<category><![CDATA[MRK]]></category>
		<category><![CDATA[MYL]]></category>
		<category><![CDATA[Mylan]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[RX]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=26385</guid>
		<description><![CDATA[The pharmaceutical industry has witnessed major changes over the past few quarters, with performance being affected by factors like sluggish prescription trends, intensifying generic competition and limited phase III catalysts. The next five years are expected to reflect a significant imbalance between new product introductions and patent losses. According to IMS Health (RX), this is the main reason global pharmaceutical market growth will be restricted to the mid-single digits through 2013. Over the next five years, products that currently generate about $137 billion in sales are expected to face generic competition Incorporatedluding Lipitor, Plavix and Seretide. At the same time, new products are not expected to generate the same level of sales as products losing patent protection. With revenue growth stalling or slowing down, companies have been resorting to cost-cutting ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/01/29/rx-pharma-biotech-stock-review-industry-outlook/26385/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(WPI) Watson Pharmaceuticals Sees 16 Analysts Raising Fourth Quarter Estimates</title>
		<link>http://www.stockbloghub.com/2010/01/27/wpi-watson-pharmaceuticals-sees-16-analysts-raising-fourth-quarter-estimates/26214</link>
		<comments>http://www.stockbloghub.com/2010/01/27/wpi-watson-pharmaceuticals-sees-16-analysts-raising-fourth-quarter-estimates/26214#comments</comments>
		<pubDate>Thu, 28 Jan 2010 01:24:20 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drugs - Generic]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Dr. Reddy's Laboratories Limited]]></category>
		<category><![CDATA[MYL]]></category>
		<category><![CDATA[Mylan]]></category>
		<category><![CDATA[Par Pharmaceutical Companies Inc]]></category>
		<category><![CDATA[PRX]]></category>
		<category><![CDATA[RDY]]></category>
		<category><![CDATA[TEVA]]></category>
		<category><![CDATA[Teva Pharmaceutical Industries Limited]]></category>
		<category><![CDATA[Watson Pharmaceuticals Inc.]]></category>
		<category><![CDATA[WPI]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=26214</guid>
		<description><![CDATA[Watson Pharmaceuticals, Inc. (WPI) reports fourth-quarter results on February 23, with the current Zacks Consensus Estimate at 72 cents per share. Estimates appear to be modestly up, with one of the 16 analysts covering the stock raising fourth quarter estimates in the last 30 days. In terms of earnings surprises, Watson had a modest positive surprise in the third quarter and a 7% positive surprise in the second quarter of 2009, with the four-quarter average of 8%. (This means, on average, Watson has come ahead of the Zacks Consensus by 8% over the last four quarters.) If quarterly results come in-line with expectations, fourth quarter 2009 EPS would be 35.8% above the year-ago level. However, chances are high that there could be a positive surprise of 1.4% for the upcoming ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/01/27/wpi-watson-pharmaceuticals-sees-16-analysts-raising-fourth-quarter-estimates/26214/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(WPI) Watson Pharmaceuticals Set to Top Expectations</title>
		<link>http://www.stockbloghub.com/2010/01/14/wpi-watson-pharmaceuticals-set-to-top-expectations/25019</link>
		<comments>http://www.stockbloghub.com/2010/01/14/wpi-watson-pharmaceuticals-set-to-top-expectations/25019#comments</comments>
		<pubDate>Thu, 14 Jan 2010 22:21:31 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drugs - Generic]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Dr. Reddy's Laboratories Limited]]></category>
		<category><![CDATA[Inc.]]></category>
		<category><![CDATA[JPM]]></category>
		<category><![CDATA[JPMorgan Chase & Company]]></category>
		<category><![CDATA[MYL]]></category>
		<category><![CDATA[Mylan]]></category>
		<category><![CDATA[Par Pharmaceutical Companies Inc]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[PRX]]></category>
		<category><![CDATA[RDY]]></category>
		<category><![CDATA[TEVA]]></category>
		<category><![CDATA[Teva Pharmaceutical Industries Limited]]></category>
		<category><![CDATA[Watson Pharmaceuticals Inc.]]></category>
		<category><![CDATA[WPI]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=25019</guid>
		<description><![CDATA[Watson Pharmaceuticals, Inc. (WPI) recently announced that it expects 2009 earnings to meet or exceed guidance provided by the company in Nov. 2009. The company had earlier guided towards earnings in the range of $2.50 &#8211; $2.58 per share. Watson also announced that it expects revenues to increase 9% year over year to $2.7 billion in 2009. The company’s shares reacted positively to the news, with the stock gaining roughly 3.5% since the announcement. The statement, which was made at the 28th Annual J.P. Morgan (JPM) Healthcare Conference, is based on a preliminary review of the company’s performance in the fourth quarter and year-ended December 31, 2009. Watson attributed the robust performance to strong contributions from its new generic and brand products, and significant growth in distribution revenues in the ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/01/14/wpi-watson-pharmaceuticals-set-to-top-expectations/25019/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(WPI) Watson Pharmaceuticals Coverage Initiated at Neutral</title>
		<link>http://www.stockbloghub.com/2010/01/10/wpi-watson-pharmaceuticals-coverage-initiated-at-neutral/24593</link>
		<comments>http://www.stockbloghub.com/2010/01/10/wpi-watson-pharmaceuticals-coverage-initiated-at-neutral/24593#comments</comments>
		<pubDate>Sun, 10 Jan 2010 23:33:23 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drugs - Generic]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Dr. Reddy's Laboratories Limited]]></category>
		<category><![CDATA[MYL]]></category>
		<category><![CDATA[Mylan]]></category>
		<category><![CDATA[Par Pharmaceutical Companies Inc]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[PRX]]></category>
		<category><![CDATA[RDY]]></category>
		<category><![CDATA[TEVA]]></category>
		<category><![CDATA[Teva Pharmaceutical Industries Limited]]></category>
		<category><![CDATA[Watson Pharmaceuticals Inc.]]></category>
		<category><![CDATA[WPI]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=24593</guid>
		<description><![CDATA[We recently initiated coverage on Watson Pharmaceuticals, Inc. (WPI) with a “Neutral&#8221; recommendation and a target price of $42. The company enjoys a strong position in the generics market. We believe the company’s strategy of developing generics that are difficult to formulate or manufacture will help strengthen its position in the market. Going forward Incorporatedreasing awareness about generics, initiatives taken by various government and private agencies encouraging the use of low-cost generics, an aging population and a corresponding increase in healthcare costs, as well as the large number of branded products losing patent protection over the coming years, should lead to continued expansion of the generics market. We also believe that Watson’s recent acquisition of Arrow will help the company expand its footprint in ex-U.S. territories, and will also boost ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/01/10/wpi-watson-pharmaceuticals-coverage-initiated-at-neutral/24593/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(AZN) AstraZeneca  is Notified That The FDA Backs Crestor&#8217;s Wider Use</title>
		<link>http://www.stockbloghub.com/2009/12/28/azn-astrazeneca-is-notified-that-the-fda-backs-crestors-wider-use/23749</link>
		<comments>http://www.stockbloghub.com/2009/12/28/azn-astrazeneca-is-notified-that-the-fda-backs-crestors-wider-use/23749#comments</comments>
		<pubDate>Tue, 29 Dec 2009 01:27:30 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[AstraZeneca plc]]></category>
		<category><![CDATA[AZN]]></category>
		<category><![CDATA[MYL]]></category>
		<category><![CDATA[Mylan]]></category>
		<category><![CDATA[Novartis AG]]></category>
		<category><![CDATA[NVS]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=23749</guid>
		<description><![CDATA[AstraZeneca (AZN) received a positive opinion from the US Food and Drug Administration’s (FDA) Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) regarding the expanded use of Crestor. AstraZeneca is seeking approval for Crestor to treat patients with normal cholesterol levels but having other risks of heart disease. The committee voted 12-4 in favor of Crestor after analyzing its benefit against possible risk in some patients. However, the committee was concerned that Crestor should not be used at random in patients with low risk. Following the recommendation, AstraZeneca has moved one step closer to FDA approval. Although the FDA is not required to follow the committee’s opinion, it generally does so. The panel’s recommendation was based on data presented from the JUPITER (Justification for the Use of statins in Prevention: an Intervention Trial ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/12/28/azn-astrazeneca-is-notified-that-the-fda-backs-crestors-wider-use/23749/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(CEPH) Cephalon Learns FDA Delays Nuvigil Decision</title>
		<link>http://www.stockbloghub.com/2009/12/28/ceph-cephalon-learns-fda-delays-nuvigil-decision/23738</link>
		<comments>http://www.stockbloghub.com/2009/12/28/ceph-cephalon-learns-fda-delays-nuvigil-decision/23738#comments</comments>
		<pubDate>Tue, 29 Dec 2009 01:25:25 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[CEPH]]></category>
		<category><![CDATA[Cephalon Inc.]]></category>
		<category><![CDATA[MYL]]></category>
		<category><![CDATA[Mylan]]></category>
		<category><![CDATA[TEVA]]></category>
		<category><![CDATA[Teva Pharmaceutical Industries Limited]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=23738</guid>
		<description><![CDATA[The U.S. Food and Drug Administration (FDA) recently informed Cephalon, Inc. (CEPH) that it will require more time to review the supplemental new drug application (sNDA) submitted by the company for Nuvigil. Cephalon had filed the sNDA in June 2009, seeking to expand Nuvigil’s label as a treatment for improving wakefulness in patients with excessive sleepiness associated with jet lag disorder due to eastbound travel. The FDA had initially granted priority review status to the candidate which means a decision would have been out by Dec 29, 2009. However, with the agency asking for additional review time, a decision is now expected by March 29, 2010. Nuvigil (armodafinil) is a follow-on version of Provigil (modafinil) which contributed about 50% to revenues in 2008. Cephalon received FDA approval for Nuvigil in ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/12/28/ceph-cephalon-learns-fda-delays-nuvigil-decision/23738/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(SLXP) Salix Pharmaceuticals to File for IBS Indication</title>
		<link>http://www.stockbloghub.com/2009/12/16/slxp-salix-pharmaceuticals-to-file-for-ibs-indication/23023</link>
		<comments>http://www.stockbloghub.com/2009/12/16/slxp-salix-pharmaceuticals-to-file-for-ibs-indication/23023#comments</comments>
		<pubDate>Wed, 16 Dec 2009 22:54:58 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Related Products]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Hawaiian Electric Industries Inc]]></category>
		<category><![CDATA[HE]]></category>
		<category><![CDATA[MYL]]></category>
		<category><![CDATA[Mylan]]></category>
		<category><![CDATA[Salix Pharmaceuticals Limited]]></category>
		<category><![CDATA[SLXP]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=23023</guid>
		<description><![CDATA[Salix Pharmaceuticals, Ltd. (SLXP) recently held a pre-NDA meeting with the U.S. Food and Drug Administration (FDA) related to the company’s new drug application (NDA) for rifaximin for the treatment of patients with non-constipation irritable bowel syndrome (non-C IBS). The meeting was conducted to discuss the completion of the company’s non-C IBS development program, the results of two phase III studies (TARGET 1 and TARGET 2), and to reach agreement on the content and format of the company’s NDA for the indication. TARGET 1 and TARGET 2 were conducted to evaluate the efficacy and safety of rifaximin 550 mg. Results showed that patients treated with rifaximin achieved a statistically significant improvement in the primary endpoint compared to placebo treated patients. Rifaximin also achieved statistical significance in the key secondary endpoint ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/12/16/slxp-salix-pharmaceuticals-to-file-for-ibs-indication/23023/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(MYL) Mylan Wins FDA Approval for Their Abbreviated New Drug Application</title>
		<link>http://www.stockbloghub.com/2009/11/14/myl-mylan-wins-fda-approval-for-their-abbreviated-new-drug-application/20490</link>
		<comments>http://www.stockbloghub.com/2009/11/14/myl-mylan-wins-fda-approval-for-their-abbreviated-new-drug-application/20490#comments</comments>
		<pubDate>Sat, 14 Nov 2009 22:37:24 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drugs - Generic]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[MYL]]></category>
		<category><![CDATA[Mylan]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=20490</guid>
		<description><![CDATA[Recently, Mylan Inc.‘s (MYL) subsidiary, Matrix Laboratories received final approval from the US Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Lansoprazole Delayed-release (DR) capsules in two dosage forms (15 mg and 30 mg). Mylan plans to begin shipment of the product immediately. The drug is the generic version of Takeda Pharmaceuticals&#8217; (TKPHY.PK) proton pump inhibitor Prevacid DR Capsules. According to IMS Health (RX), the branded version had US sales of approximately $3 billion for the 12 months ending June 30. Mylan received quite a few approvals in the recent past. In October, Mylan settled its dispute with Pfizer (PFE) related to the patent of antifungal drug Vfend (voriconazole), following which Mylan received the approval to launch the generic version of the drug. Additionally, in ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/11/14/myl-mylan-wins-fda-approval-for-their-abbreviated-new-drug-application/20490/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(RX) Big Pharma and Biotech &#8211; Industry Outlook</title>
		<link>http://www.stockbloghub.com/2009/11/09/rx-big-pharma-and-biotech-industry-outlook/20146</link>
		<comments>http://www.stockbloghub.com/2009/11/09/rx-big-pharma-and-biotech-industry-outlook/20146#comments</comments>
		<pubDate>Mon, 09 Nov 2009 23:57:38 +0000</pubDate>
		<dc:creator>Shawn</dc:creator>
				<category><![CDATA[Research Services]]></category>
		<category><![CDATA[Services]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[ACL]]></category>
		<category><![CDATA[ACOR]]></category>
		<category><![CDATA[Acorda Therapeutics Inc]]></category>
		<category><![CDATA[Alcon Inc]]></category>
		<category><![CDATA[Alkermes]]></category>
		<category><![CDATA[ALKS]]></category>
		<category><![CDATA[AstraZeneca plc]]></category>
		<category><![CDATA[AZN]]></category>
		<category><![CDATA[BIIB]]></category>
		<category><![CDATA[Biogen Idec Inc]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[GENZ]]></category>
		<category><![CDATA[Genzyme Corporation]]></category>
		<category><![CDATA[GILD]]></category>
		<category><![CDATA[Gilead Sciences Inc]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[IMS Health Inc.]]></category>
		<category><![CDATA[Inc.]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[LLY]]></category>
		<category><![CDATA[MannKind Corporation]]></category>
		<category><![CDATA[Merck & Company Inc]]></category>
		<category><![CDATA[MNKD]]></category>
		<category><![CDATA[MRK]]></category>
		<category><![CDATA[MYL]]></category>
		<category><![CDATA[Mylan]]></category>
		<category><![CDATA[Novartis AG]]></category>
		<category><![CDATA[NVS]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[RX]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[Schering-Plough Corporation]]></category>
		<category><![CDATA[SGP]]></category>
		<category><![CDATA[SNY]]></category>
		<category><![CDATA[WYE]]></category>
		<category><![CDATA[Wyeth]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=20146</guid>
		<description><![CDATA[The pharmaceutical industry has witnessed major changes in 2009. Performance has been affected by factors like sluggish prescription trends, intensifying generic competition and limited phase III catalysts. The next five years are expected to reflect a significant imbalance between new product introductions and patent losses. According to IMS Health (RX), this is the main reason why global pharmaceutical market growth will be restricted to the mid-single digits through 2013. Over the next five years, products that currently generate about $137 billion in sales are expected to face generic competition Incorporatedluding Lipitor, Plavix and Seretide. At the same time, new products are not expected to generate the same level of sales as the products losing patent protection have. With most of the big pharma companies already facing patent challenges for their ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/11/09/rx-big-pharma-and-biotech-industry-outlook/20146/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(TEVA) Teva Pharmaceutical Industries Reports Strong Quarter</title>
		<link>http://www.stockbloghub.com/2009/11/04/teva-teva-pharmaceutical-industries-reports-strong-quarter/19689</link>
		<comments>http://www.stockbloghub.com/2009/11/04/teva-teva-pharmaceutical-industries-reports-strong-quarter/19689#comments</comments>
		<pubDate>Wed, 04 Nov 2009 22:09:37 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Advanced Photonix Inc.]]></category>
		<category><![CDATA[API]]></category>
		<category><![CDATA[Inc.]]></category>
		<category><![CDATA[MYL]]></category>
		<category><![CDATA[Mylan]]></category>
		<category><![CDATA[TEVA]]></category>
		<category><![CDATA[Teva Pharmaceutical Industries Limited]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=19689</guid>
		<description><![CDATA[Teva Pharmaceutical Industries Ltd. (TEVA) reported earnings of 89 cents in the third quarter of 2009, up 16% from the year-ago period and a cent above the Zacks Consensus Estimate. Strong sales of Copaxone and in the respiratory business helped drive earnings in the reported quarter. Net sales increased 25% to $3.55 billion, with the Barr acquisition contributing to sales across different geographical segments. The strengthening U.S. dollar adversely impacted net sales by $160 million or 6%. Revenue performance across key business segments was mixed. While the Pharmaceuticals Sales segment posted growth of 27% with revenues coming in at $3.4 billion, the active pharmaceutical ingredients (API) segment reported an 8% decline in growth with sales coming in at $136 million. Pharmaceutical segment sales were driven by strong performances in the ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/11/04/teva-teva-pharmaceutical-industries-reports-strong-quarter/19689/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(MYL) Mylan Beats Expectations &#8211; Raises Outlook</title>
		<link>http://www.stockbloghub.com/2009/11/01/myl-mylan-beats-expectations-raises-outlook/19236</link>
		<comments>http://www.stockbloghub.com/2009/11/01/myl-mylan-beats-expectations-raises-outlook/19236#comments</comments>
		<pubDate>Sun, 01 Nov 2009 23:20:23 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drugs - Generic]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[MYL]]></category>
		<category><![CDATA[Mylan]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=19236</guid>
		<description><![CDATA[Mylan, Inc. (MYL) reported third quarter earnings per share of 32 cents, above both the Zacks Consensus Estimate of 27 cents and 23 cents in the prior-year period. The company reported revenues of $1.26 billion, a 24% decline from the year-ago period. However, the year-ago period included $455 million of revenue related to the sale of the product rights of Bystolic. Excluding this, total revenues increased 5.2% over the third quarter 2008. Revenues would have increased 9%, but for the unfavorable movement of foreign currency. From this quarter onwards, Mylan has decided to report its results in two segments &#8212; Generics and Specialty &#8212; following the acquisition of approximately 24% of the remaining interest in Matrix and the related de-listing. The former Matrix segment has been included in the Generics ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/11/01/myl-mylan-beats-expectations-raises-outlook/19236/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(MYL) Mylan Settles Dispute with Pfizer</title>
		<link>http://www.stockbloghub.com/2009/10/16/myl-mylan-settles-dispute-with-pfizer/17812</link>
		<comments>http://www.stockbloghub.com/2009/10/16/myl-mylan-settles-dispute-with-pfizer/17812#comments</comments>
		<pubDate>Fri, 16 Oct 2009 23:40:47 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drugs - Generic]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[MYL]]></category>
		<category><![CDATA[Mylan]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=17812</guid>
		<description><![CDATA[Recently, Mylan (MYL) announced the settlement of its dispute with Pfizer (PFE) related to the patent of antifungal drug Vfend (voriconazole). Now Mylan can launch an authorized generic version of the drug in two dosage forms of 50 mg and 200 mg tablets in early 2011. Mylan’s subsidiary, Matrix Laboratories, has Food and Drug Administration (FDA) approval for the generic version of the drug. Being the first company to submit an Abbreviated New Drug Application (ANDA), Matrix expects to be eligible to receive 180 days of marketing exclusivity for the drug. However, the agreement does not include liquid or intravenous versions of Vfend. The agreement has yet to be approved by the US Department of Justice and the Federal Trade Commission. Vfend recorded sales of $164 million in the 12 ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/10/16/myl-mylan-settles-dispute-with-pfizer/17812/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(GSK) Pharma Majors to Gain from India</title>
		<link>http://www.stockbloghub.com/2009/08/19/gsk-pharma-majors-to-gain-from-india/12677</link>
		<comments>http://www.stockbloghub.com/2009/08/19/gsk-pharma-majors-to-gain-from-india/12677#comments</comments>
		<pubDate>Wed, 19 Aug 2009 22:21:16 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Dr. Reddys Laboratories]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[Merck & Company Inc.]]></category>
		<category><![CDATA[MRK]]></category>
		<category><![CDATA[MYL]]></category>
		<category><![CDATA[Mylan]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[RDY]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>
		<category><![CDATA[WYE]]></category>
		<category><![CDATA[Wyeth]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=12677</guid>
		<description><![CDATA[All major pharmaceutical companies that have operations in India are likely to benefit from the latest decision made by the Commerce Ministry in that country. The ministry accepted the Mashelkar committee’s report, according to which India will continue to allow patents on incremental innovations if the enhancements are beneficial to patients. The decision was taken amidst severe protests from generic players and health activists who fear this will not allow cheaper generic drugs to enter the market. On the basis of 2008 sales figures, the Indian pharmaceutical market ranks 13th in the world, with sales of $7.7bn last year (an increase of 4% over 2007). The rapidly growing middle income group with higher disposable income makes it an attractive place for major pharma companies. The pharmaceutical market is expected to ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/08/19/gsk-pharma-majors-to-gain-from-india/12677/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(SGP) Schering-Plough Settles Lawsuits &#8211; Analyst Blog</title>
		<link>http://www.stockbloghub.com/2009/08/12/sgp-schering-plough-settles-lawsuits-analyst-blog/12445</link>
		<comments>http://www.stockbloghub.com/2009/08/12/sgp-schering-plough-settles-lawsuits-analyst-blog/12445#comments</comments>
		<pubDate>Thu, 13 Aug 2009 00:22:55 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Caraco Pharmaceutical Laborato]]></category>
		<category><![CDATA[CPD]]></category>
		<category><![CDATA[Dr. Reddys Laboratories]]></category>
		<category><![CDATA[GeoPharma Inc.]]></category>
		<category><![CDATA[GORX]]></category>
		<category><![CDATA[Merck & Company Inc.]]></category>
		<category><![CDATA[MRK]]></category>
		<category><![CDATA[MYL]]></category>
		<category><![CDATA[Mylan]]></category>
		<category><![CDATA[Perrigo Company]]></category>
		<category><![CDATA[PRGO]]></category>
		<category><![CDATA[RDY]]></category>
		<category><![CDATA[Schering-Plough Corp.]]></category>
		<category><![CDATA[SGP]]></category>
		<category><![CDATA[Watson Pharmaceuticals Inc.]]></category>
		<category><![CDATA[WPI]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=12445</guid>
		<description><![CDATA[Yesterday, Schering-Plough Corp. (SGP) said it has signed an agreement with Orchid Chemicals &#38; Pharmaceuticals Ltd. and Orgenus Pharma Inc., which sought to make generic versions of its allergy drug Clarinex. This signals the end of all pending litigations that Schering filed against several generic drug manufacturing companies in the US District Court of New Jersey since 2006. These companies wanted to market solid oral doses of the drug, desloratadine, in the U.S. as generic brands before the expiration of certain Schering patents. Pursuant to the agreement, Orchid received rights to launch a generic version of the Clarinex brand Reditabs in the U.S. on Jan. 1, 2012 and Clarinex brand 5 milligram tablets on July 1 of that year. Schering holds various patents related to Clarinex till 2022. Schering has ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/08/12/sgp-schering-plough-settles-lawsuits-analyst-blog/12445/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>

